Interleukin Patents (Class 424/85.2)
-
Patent number: 11324822Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.Type: GrantFiled: March 18, 2016Date of Patent: May 10, 2022Assignee: Syndax Pharmaceuticals, Inc.Inventors: Robert Goodenow, Peter Ordentlich
-
Patent number: 11324746Abstract: The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.Type: GrantFiled: December 22, 2015Date of Patent: May 10, 2022Assignee: AROVELLA THERAPEUTICS LIMITEDInventors: Stephen Damment, Richard Franklin, Jorge D. Erusalimsky
-
Patent number: 11318185Abstract: The present invention addresses the problem of finding a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer containing as an active ingredient: (a) a polypeptide consisting of any one of the amino acid sequences represented by SEQ ID NOs: 3 to 45; or (b) a polypeptide comprising one to several amino acid deletions, substitutions or additions in the amino acid sequence of the polypeptide (a); is useful as an agent for treating or preventing cancer, etc.Type: GrantFiled: March 1, 2017Date of Patent: May 3, 2022Assignee: TORAY INDUSTRIES, INC.Inventors: Akira Kurihara, Fumiyoshi Okano
-
Patent number: 11311618Abstract: The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.Type: GrantFiled: December 15, 2016Date of Patent: April 26, 2022Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, GLAXOSMITHKLINE BIOLOGICALS SA, SORBONNE UNIVERSITEInventors: Sandra Morel, Charlotte Véronique Pouchy, Benoit Laurent Salomon, Nathalie Raoul Liliane Vanerheyde
-
Patent number: 11311613Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.Type: GrantFiled: November 6, 2017Date of Patent: April 26, 2022Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang
-
Patent number: 11304990Abstract: The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.Type: GrantFiled: January 19, 2018Date of Patent: April 19, 2022Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)Inventors: Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
-
Patent number: 11298380Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.Type: GrantFiled: January 1, 2019Date of Patent: April 12, 2022Assignees: Khloris Biosciences, Inc., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Nigel G. Kooreman, Joseph C. Wu, Lynne A. Bui
-
Patent number: 11291747Abstract: Disclosed are a biosealant system and method for treatment of a pulmonary air leak comprising applying the biosealant system to the locus of the air leak.Type: GrantFiled: April 1, 2019Date of Patent: April 5, 2022Assignee: The Trustees of Columbia University in The City of New YorkInventors: Matthew Bacchetta, Brandon Guenthart, Jinho Kim, John O'Neill, Gordana Vunjak-Novakovic
-
Patent number: 11293009Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.Type: GrantFiled: January 5, 2021Date of Patent: April 5, 2022Assignee: Iovance Biotherapeutics, Inc.Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
-
Patent number: 11285192Abstract: The present specification provides compositions of ?-endorphin and adrenocorticotropic hormone (ACTH). These compositions are useful in methods of treating disease.Type: GrantFiled: August 31, 2020Date of Patent: March 29, 2022Assignee: Adamis Pharmaceuticals CorporationInventors: Charles Peter Lollo, Dennis J. Carlo
-
Patent number: 11278608Abstract: Provided herein are nicotine polymer-stabilized nanoparticles, formulations thereof, and vaccines. Also provided herein are methods of treating and/or preventing nicotine addiction in a subject in need thereof.Type: GrantFiled: January 5, 2017Date of Patent: March 22, 2022Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Chenming Zhang, Zongmin Zhao, Yun Hu
-
Patent number: 11273204Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15R? or derivatives thereof; and uses thereof.Type: GrantFiled: August 8, 2014Date of Patent: March 15, 2022Assignees: CYTUNE PHARMA, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)Inventors: Alain Gey, Eric Tartour, David Bechard
-
Patent number: 11260118Abstract: The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. The present invention further relates to the use of a peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.Type: GrantFiled: March 15, 2018Date of Patent: March 1, 2022Assignee: Cancer Research MalaysiaInventors: San Jiun Chai, Sammuel Chee Yong Fong, Chai Phei Gan, Sathibalan Ponniah, Vyomesh Patel, Sok Ching Cheong, Kue Peng Lim
-
Patent number: 11260116Abstract: The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.Type: GrantFiled: May 3, 2017Date of Patent: March 1, 2022Assignee: IMMUNOVACCINE TECHNOLOGIES INC.Inventors: Marianne Stanford, Genevieve Weir, Frederic Ors, Leeladhar Sammatur
-
Patent number: 11246908Abstract: The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.Type: GrantFiled: January 10, 2019Date of Patent: February 15, 2022Assignee: The Johns Hopkins UniversityInventors: T. C. Wu, Chien-Fu Hung, Brandon Krishna Lam
-
Patent number: 11248050Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.Type: GrantFiled: October 16, 2020Date of Patent: February 15, 2022Assignee: Alkermes Pharma Ireland LimitedInventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist
-
Patent number: 11246891Abstract: The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.Type: GrantFiled: February 3, 2020Date of Patent: February 15, 2022Assignee: Micro Vascular Tissues, Inc.Inventors: Dale R. Peterson, Ralph-Heiko Mattern, Kevin L. Ohashi, Lael J. Pickett, Glen Gong, Mohammad A. El-Kalay
-
Patent number: 11229668Abstract: Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.Type: GrantFiled: February 8, 2018Date of Patent: January 25, 2022Assignees: NantCell, Inc., Nant Holdings IP, LLCInventors: Shahrooz Rabizadeh, Kayvan Niazi, Patrick Soon-Shiong, Hing Wong, Wenxin Xu
-
Patent number: 11224573Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.Type: GrantFiled: September 16, 2020Date of Patent: January 18, 2022Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul
-
Patent number: 11203630Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: GrantFiled: August 23, 2019Date of Patent: December 21, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
-
Patent number: 11191746Abstract: The present invention relates to a composition for inhibiting the growth of cancer stem cells, which includes ciclesonide or a pharmaceutically acceptable salt thereof as an active ingredient, a pharmaceutical composition or food composition for inhibiting cancer metastasis, or treating or preventing cancer, which includes the composition, and the like. Ciclesonide of the present invention inhibits the growth of breast cancer cells and lung cancer cells, and inhibits the formation of breast cancer stem cells and lung cancer stem cells.Type: GrantFiled: October 13, 2017Date of Patent: December 7, 2021Assignee: JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Dong-sun Lee, Hack Sun Choi
-
Patent number: 11191821Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.Type: GrantFiled: February 27, 2017Date of Patent: December 7, 2021Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Robert Seder, Geoffrey Lynn
-
Patent number: 11179420Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.Type: GrantFiled: April 27, 2017Date of Patent: November 23, 2021Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Yoshifumi Ikeyama, Eiko Uno, Masayo Yumoto, Mihoko Yoshino, Xuan Trung Ngo, Hiroyuki Nishida, Akiko Uetani
-
Patent number: 11167034Abstract: This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.Type: GrantFiled: June 13, 2018Date of Patent: November 9, 2021Assignee: The University of British ColumbiaInventors: John K. Jackson, Martin E. Gleave, Veronika Schmitt, Claudia Kesch
-
Patent number: 11160848Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.Type: GrantFiled: August 15, 2019Date of Patent: November 2, 2021Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCESInventor: James K. Williams
-
Patent number: 11162072Abstract: The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.Type: GrantFiled: January 6, 2020Date of Patent: November 2, 2021Assignees: BIONTECH US INC., Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek ZiekenhuisInventors: Marit M. Van Buuren, Divya Reddy Lenkala, Joost Huibert Van Den Berg, Jessica Kohler, Matthew Goldstein, Ed Fritsch, Renate De Boer, Ton Schumacher, Noor Bakker
-
Patent number: 11161897Abstract: Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.Type: GrantFiled: July 17, 2018Date of Patent: November 2, 2021Assignee: Janssen Biotech, Inc.Inventors: Chichi Huang, John Lee, Jill Mooney, Michael Naso
-
Patent number: 11154571Abstract: Provided are exosomes sourced from a granulocyte myeloid-derived suppressor cell and an application thereof. The exosomes are named as G-MDSC exo. Also provided is a use of the exosomes in preparing a drug used for suppressing autoimmune diseases. The G-MDSC exo can effectively suppress proliferation of CD4+T cells in vitro, promote induced proliferation of T regulatory (Treg) cells, alleviate foot swelling of model mice having delayed-type hypersensitivity, and suppress attacks of inflammatory bowel disease (IBD) and collagen-induced arthritis (CIA) of the mice.Type: GrantFiled: April 30, 2015Date of Patent: October 26, 2021Assignee: JIANGSU UNIVERSITYInventors: Shengjun Wang, Yungang Wang, Jie Tian, Ke Rui, Jie Ma, Bin Ma, Xinyi Tang, Huaxi Xu
-
Patent number: 11149074Abstract: The present invention provides a means capable of efficiently manufacturing a fused substance of an Fc protein and a substance of interest (for example, a peptide). Specifically, the present invention provides an azide group-containing Fc protein represented by formula (1): N3-La-Phe-Lb-Fc??(1) wherein N3 represents an azide group; La represents a bond or a divalent group; Phe represents a residue of phenylalanine or a derivative thereof; Lb represents a lysine residue or an arginine residue, or a peptide linker containing two or more amino acid residues having a lysine residue or an arginine residue at/on the N-terminus; and Fc represents an Fc protein; and the like.Type: GrantFiled: November 1, 2018Date of Patent: October 19, 2021Assignee: Ajinomoto Co., Inc.Inventors: Shigeo Hirasawa, Masumi Taki
-
Patent number: 11149071Abstract: The present invention provides a recombinant fusion protein. The fusion protein is formed by the fusion of D2 domain of Slit2 protein and HSA protein, and the position 386 amino acid of the Slit2 protein molecule is serine.Type: GrantFiled: November 21, 2019Date of Patent: October 19, 2021Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.Inventors: Huashun Li, Baoyong Ren, Peng Liu
-
Patent number: 11130791Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.Type: GrantFiled: November 20, 2018Date of Patent: September 28, 2021Assignee: Genentech, Inc.Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
-
Patent number: 11129846Abstract: Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.Type: GrantFiled: August 13, 2019Date of Patent: September 28, 2021Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Anuradha Ray, Prabir Ray, Timothy B. Oriss, Sally Ellen Wenzel
-
Patent number: 11130809Abstract: Provided herein are pharmaceutical formulations for anti-PD-1 antibodies.Type: GrantFiled: July 17, 2017Date of Patent: September 28, 2021Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Wei Cao, Junfeng Li, Xiaolin Liu
-
Patent number: 11130792Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.Type: GrantFiled: February 8, 2019Date of Patent: September 28, 2021Assignee: Scott & White Memorial HospitalInventor: Arthur E. Frankel
-
Patent number: 11116771Abstract: Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided.Type: GrantFiled: January 30, 2017Date of Patent: September 14, 2021Assignee: Oncoceutics, Inc.Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
-
Patent number: 11116752Abstract: Disclosed is a pharmaceutical composition containing a bicyclo-substituted pyrazolone azo derivative or a salt thereof and a preparation method thereof. In particular, the pharmaceutical composition disclosed in the present invention contains (Z)-5-(2-hydroxyl-3-(2-(3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalene-2-yl)-1H-pyrazol-4(5H)-ylidene)hydrazino)phenyl)furan-2-carboxylic acid or a pharmaceutically acceptable salt thereof, and at least one filler optionally selected from cellulose, microcrystalline cellulose, lactose and starch. The composition has a good stability, dissolution rate and bioavailability, and the preparation process is simple, economical and quick.Type: GrantFiled: January 16, 2017Date of Patent: September 14, 2021Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Yun Lu, Xinhua Zhang, Daimei Zhang
-
Patent number: 11110157Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.Type: GrantFiled: April 15, 2019Date of Patent: September 7, 2021Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jan C. Schmollinger
-
Patent number: 11098100Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.Type: GrantFiled: October 6, 2016Date of Patent: August 24, 2021Assignee: Regents of the University of MinnesotaInventors: Daniel Attilio Vallera, Jeffrey S. Miller
-
Patent number: 11098101Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.Type: GrantFiled: September 5, 2019Date of Patent: August 24, 2021Assignee: Regents of the University of MinnesotaInventors: Daniel Attilio Vallera, Jeffrey S. Miller
-
Patent number: 11098099Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant IL-2 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of autoimmune diseases and immune-mediated inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: GrantFiled: February 4, 2015Date of Patent: August 24, 2021Assignee: HOFFMANN-LA ROCHE INC.Inventors: Christian Klein, Pablo Umana, Ekkehard Moessner, Ralf Hosse, Laurence Bernard Peterson, Linda Wicker
-
Patent number: 11078535Abstract: Compositions and methods are provided for the early detection of neuroinflammation in a patient in a presymptomatic stage of a neurodegenerative disease. The method comprises identifying patients with elevated expression levels of a micro RNA selected from the group consisting of miR142-3p, miR142-5p, miR181a, miR181b, miR219-3p and miR219-5p. The identified patients can then be treated with a therapeutic pharmaceutical composition comprising antimiR oligonucleotides.Type: GrantFiled: July 7, 2018Date of Patent: August 3, 2021Assignee: The Trustees of Indiana UniversityInventors: Salil Sharma, Hui-Chen Lu
-
Patent number: 11065330Abstract: The invention relates to a pharmaceutical composition for modulation of T cell and B cell responses by antigen- or allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, made of one or more preparations and comprising one or more matrices suitable for locally restricted sustained release of a physiologically effective dose of at least one antigen or allergen, liposomes tailored for effective phagocytosis, one or more immune modulators of phagocytosis, and one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells at the site of antigen or allergen presentation.Type: GrantFiled: March 10, 2015Date of Patent: July 20, 2021Assignee: PLS-Design GmbHInventors: Reinhard Bredehorst, Thomas Grunwald, Carsten Schmidt-Weber
-
Patent number: 11058664Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: GrantFiled: May 15, 2019Date of Patent: July 13, 2021Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
-
Patent number: 11045418Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.Type: GrantFiled: March 30, 2016Date of Patent: June 29, 2021Assignees: BioNTech RNA Pharmaceuticals GmbH, Tron-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat MainzInventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer
-
Patent number: 11041008Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.Type: GrantFiled: September 6, 2018Date of Patent: June 22, 2021Assignee: The Government of the United States of America as Represented by The Secretary of the Department of Health and Human ServicesInventors: Cristina Bergamaschi, Barbara K. Felber, George N. Pavlakis, Antonio Valentin
-
Patent number: 11020467Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.Type: GrantFiled: May 25, 2018Date of Patent: June 1, 2021Assignee: Etubics CorporationInventors: Frank R. Jones, Adrian Rice, Elizabeth Gabitzsch, Yvette Latchman, Joseph Balint
-
Patent number: 11008405Abstract: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognising said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to methods of producing said antibodies, methods of inhibiting MASP-2 activity as well as to pharmaceutical compositions comprising the MASP-2 antibodies.Type: GrantFiled: January 7, 2020Date of Patent: May 18, 2021Assignee: Helion Biotech ApSInventors: Flemming Larsen, Ulla Wahlers
-
Patent number: 11008404Abstract: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognising said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to methods of producing said antibodies, methods of inhibiting MASP-2 activity as well as to pharmaceutical compositions comprising the MASP-2 antibodies.Type: GrantFiled: December 4, 2018Date of Patent: May 18, 2021Assignee: Helion Biotech ApSInventors: Flemming Larsen, Ulla Wahlers
-
Patent number: 11007222Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.Type: GrantFiled: December 9, 2019Date of Patent: May 18, 2021Assignee: NEXIMMUNE, INC.Inventors: Mathias Oelke, Kristi Jones, Sojung Kim, Lauren Suarez, Ken Carter, Scott Carmer, Dan Bednarik, Vineetha Edavana, Emily Lu
-
Patent number: 10994027Abstract: Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5? to 3? orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.Type: GrantFiled: February 23, 2017Date of Patent: May 4, 2021Assignee: Provecs Medical GmbHInventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer